Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-10-31

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a research study to compare the efficacy of aspirin (acetylsalicylic acid) and pneumatic compression devices versus enoxaparin (also known as Lovenox) and pneumatic compression devices in preventing deep vein thrombosis in patients with pelvic and lower extremity malignant tumors and undergoing surgery. Pneumatic compression devices are also known as sequential compression devices and are inflatable compression sleeves that are placed around patient's legs to reduce the risk of clot formation deep vein thrombosis. Pneumatic compression devices are made of a soft material that wraps around the lower leg and periodically squeeze the calf. A deep vein thrombosis is a blood clot. Most hospitalized patients wear these as a preventive measure. Pneumatic compression devices alone are not sufficient to prevent deep vein thrombosis formation. Therefore, medicines, such as aspirin and enoxaparin are utilized. Both drugs are used for prevention, but there are no studies in patients with musculoskeletal tumors which have determined whether one drug is better than another. The knowledge gained from this study will determine whether aspirin and pneumatic compression devices is the same or better than enoxaparin and pneumatic compression devices in preventing deep vein thrombosis in this patient population and may result in fewer wound and bleeding complications

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology

NCT03244020

Sarcoma Soft Tissue Sarcoma Bone Sarcoma +4 more

ENROLLING_BY_INVITATION PHASE4

Outcomes Study in Patients Receiving Aspirin With Mechanical Compression Devices Versus Aspirin Alone Following Knee and Hip Arthroplasty

NCT03027167

DVT - Deep Vein Thrombosis PE - Pulmonary Thromboembolism

WITHDRAWN PHASE4

Evaluating the Need for Pneumatic Compression Devices

NCT02641080

Osteoarthritis

COMPLETED NA

Anti-Platelet and Statin Therapy to Prevent Cancer-Associated Thrombosis

NCT02285738

Solid Tumor Cancer

COMPLETED EARLY_PHASE1

Implementing a Tool to Identify Risk for Venous Thromboembolism in Cancer Patients

NCT01602432

Venous Thromboembolism Deep-Vein Thrombosis Pulmonary Embolism +1 more

WITHDRAWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. To perform a randomized prospective study to determine efficacy of acetylsalicylic acid (ASA)+pneumatic compression device (PCD) prophylaxis compared to low-molecular weight heparin (LMWH)+PCD in patients undergoing orthopaedic procedures for musculoskeletal neoplasms (MSN) of the pelvis and lower extremity.

II. To prove that ASA+PCD is clinically equivalent to or better than LMWH+PCD in providing deep vein thrombosis (DVT) prophylaxis in this patient population and results in fewer major bleeding complications.

III. To measure rates of postoperative DVT and pulmonary embolism (PE) as primary outcomes.

SECONDARY OBJECTIVES:

I. To measure secondary outcomes including rates of readmission, reoperation, bleeding complications (including hematoma formation and prolonged wound drainage), and death.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive acetylsalicylic acid orally (PO) twice daily (BID) and wear PCD on days 1-28 after surgery.

ARM II: Patients receive enoxaparin subcutaneously (SC) once daily (QD) and wear PCD on days 1-28 after surgery.

After completion of study treatment, patients are followed up at 2 weeks, 6 weeks, and 3 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bone Metastases Musculoskeletal Cancer Soft Tissue Sarcoma Thromboembolism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm I (acetylsalicylic acid and PCD)

Patients receive acetylsalicylic acid orally PO BID and wear PCD on days 1-28 after surgery.

Group Type EXPERIMENTAL

acetylsalicylic acid

Intervention Type DRUG

325 mg twice a day

PCD

Intervention Type DEVICE

Wear PCD (Flowtron calf compression). Patients will continue to use PCDs for the duration of their hospitalization. If patients refuse to wear the PCDs, they will be withdrawn from the study.

Arm II (enoxaparin and PCD)

Patients receive enoxaparin subcutaneously SC QD and wear PCD on days 1-28 after surgery.

Group Type EXPERIMENTAL

enoxaparin

Intervention Type DRUG

40 mg once daily

PCD

Intervention Type DEVICE

Wear PCD (Flowtron calf compression). Patients will continue to use PCDs for the duration of their hospitalization. If patients refuse to wear the PCDs, they will be withdrawn from the study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

acetylsalicylic acid

325 mg twice a day

Intervention Type DRUG

enoxaparin

40 mg once daily

Intervention Type DRUG

PCD

Wear PCD (Flowtron calf compression). Patients will continue to use PCDs for the duration of their hospitalization. If patients refuse to wear the PCDs, they will be withdrawn from the study.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ASA Ecotrin Empirin Extren Enoxaparin Sodium Lovenox thromboembolism prophylaxis Flowtron calf compression

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

-Scheduled or to be scheduled for surgery performed on neoplasms of the pelvis or lower limbs, including both primary musculoskeletal lesions as well as metastatic lesions; these neoplasms may include major tumor resections, metastatic and pathologic fractures of the hip and lower extremities (LE), open biopsies, and primary malignant tumors; an active malignant neoplasm must be present at the time of surgery

Exclusion Criteria

* Prior history of DVT or PE
* Previously placed vena cava filter
* No detectable malignant disease at the time of operation
* Previous arterial thrombosis (myocardial infarction \[MI\], cerebral vascular accident \[CVA\])
* Severe platelet dysfunction (uremia, medications, dysplastic hematopoiesis); excluded if platelets \< 50,000
* Preoperative anticoagulation or active/serious bleeding in past 2 weeks (prothrombin time \[PT\] \& partial thromboplastin time \[PTT\] \> 1.6 \& \> 35)
* Hypersensitivity or allergy to aspirin or heparin (including those diagnosed with heparin-induced thrombocytopenia)
* Conditions associated with bleeding (active ulcer disease, recent neurosurgery, bleeding disorders)
* Patients with renal insufficiency (creatinine \[Cr\] \> 1.5)
* Pregnant patients
* Epidural anesthesia

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No